Kelvin Davies
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Kelvin Davies is a Professor at the Albert Einstein College of Medicine in the United States. His research focuses on erectile dysfunction, specifically related to cavernous nerve injury and its implications following pelvic surgery. He has contributed to understanding the synergistic effects of nitric oxide and PDE5 inhibitors, as well as the role of Opiorphin genes in prostate cancer growth. His recent work also explores the impacts of hyperglycemia on bladder detrusor function.
Recent Grants
Grant: Close
The microtubule cytoskeleton as a novel target for cavernous nerve regeneration after prostatectomy
Open Date: 2017-04-01
Close Date: 2021-03-31
Grant: Close
Evidence for a Distinct Gut Microbiome in Kidney Stone Formers
Open Date: 2016-08-18
Close Date: 2018-07-31
Grant: Close
Opiorphin as a master regulator of pathways leading to priapism
Open Date: 2016-01-15
Close Date: 2020-11-30
Grant: Close
Involvement of opiorphins and polyamine synthesis in the development of priapism
Open Date: 2011-09-15
Close Date: 2015-07-31
Grant: Close
Opiorphin as a master regulator of pathways leading to priapism
Open Date: 2009-09-15
Close Date: 2016-08-31
Articles (6)
Year:
2026
This study aimed to evaluate the effectiveness of combining a nitric oxide microparticle delivery system (NO-MP) with various FDA-approved PDE5 inhibitors (PDE5i) for improving erectile responses in a rat model of erectile dysfunction (ED) following cavernous nerve injury, similar to the effects of radical prostatectomy. Male Sprague-Dawley rats, 4–5 months old (weighing ~275 g) underwent bilateral cavernous nerve transection. One week post-surgery animals were administered PDE5i via oral gavage (sildenafil 0.05 mg/kg ( N = 9), tadalafil 0.005 mg/kg ( N = 8), vardenafil 0.01 mg/kg ( N = 7), avanafil 0.1 mg/kg ( N = 8) or untreated ( N = 5) followed by topical application of 250 mg NO-MP to the penile dermis. Erectile responses were assessed by measuring intracorporeal pressure (ICP) and systemic blood pressure (BP) after the application of NO-MP. Compared to NO-MP alone, combination therapy with a PDE5i significantly ( P < 0.05) reduced the time to initial erectile response from 63 ± 21.6 min to 8–23 min (vardenafil: 23 ± 2.3, avanafil: 11 ± 8.1, sildenafil: 19.9 ± 9.8, tadalafil: 18 ± 12.8), and increased the frequency of spontaneous erections from 1 ± 0.71 to 1.7–2.7 per hour (vardenafil: 2.1 ± 0.9, avanafil: 2.7 ± 1.1, sildenafil: 1.7 ± 0.6, tadalafil: 2.5 ± 0.8). No significant changes in maximal ICP/BP, duration of erectile response or baseline ICP/BP were observed. These results suggest that combining NO-MP with PDE5i may provide a promising approach for treating ED after radical prostatectomy.
Year:
2025
Year:
2022
Year:
2022
Year:
2021
Year:
2020
Make your next move.
Prepare your application
Review drafts before you send them.